The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Primorus Adds Three Directors To Board

Wed, 23rd Sep 2020 19:22

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and not separately reported by Alliance News:

----------

Primorus Investments PLC - investment firm focussed on natural resources sector - Appoints Rupert Labrum, Hedley Clark and Matthew Beardmore as directors, subject to due diligence checks, following request from unnamed investor who initially sought to requisition general meeting. Donald Strang to step down when new additions join board but Executive Chair Jeremy Taylor-Firth and Executive Director Alastair Clayton to remain. Primorus notes that notice to requisition general meeting has been withdrawn.

----------

Templeton Emerging Markets IT PLC - emerging markets investor - Adds Medha Samant to board as non-executive director from October 1. Spent about 10 years as investment director for Asian equities at Fidelity International.

----------

Asimilar Group PLC - technology-focused investor - Mark Horrocks joins immediately as non-executive director. "He has worked as a research analyst and fund manager for a FTSE100 insurance group," Asimilar notes. Donald Stewart to step down from board at the conclusion of company annual general meeting.

----------

BB Healthcare Trust PLC - healthcare-focused investor - Appoints Toby Young as non-executive director immediately. "Professor Young is a practicing frontline NHS consultant urological surgeon, director of medical Innovation at Anglia Ruskin University, president of the Institute of Decontamination Sciences, and national clinical director for Innovation for the NHS," BB Healthcare said.

----------

4d Pharma PLC - drug developer - Adds Katrin Rupalla to board as non-executive director with immediate effect. Chief Executive Officer Duncan Peyton said: "We are delighted to be able to attract someone of Katrin's calibre to our board of directors. Her vast experience guiding novel therapies through the clinic will be invaluable as we progress our pipeline of novel live biotherapeutics into and through the clinic."

----------

Hurricane Energy PLC - Goldaming, England-based oil exploration company - Non-executive Director Alan Parsley retired with effect Wednesday. Leonard Tao also steps down as alternate.

----------

Base Resources Ltd - Australia-based mineral sands producer and developer - Appoints Janine Herzig to board as non-executive director from October 12. "Ms Herzig has 30 years' experience in the resources sector, encompassing executive management, consulting, technical and production roles, across all commodities including industrial minerals," Base said. Sam Willis to step down as a non-executive director from November 20.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
14 May 2018 16:11

UK Shareholder Meetings Calendar - Next 7 Days

Tuesday 15 MayAmerisur ResourcesMacfarlane GroupSpirax-Sarco EngineeringAnglo Pacific

Read more
8 May 2018 10:02

4D Pharma Sets Up Phase Two Study For Bowel Syndrome Treatment Blautix

LONDON (Alliance News) - Biotherapeutics developer 4D Pharma PLC said on Tuesday that the US Food & Drug Administration has cleared the Investigational New Drug Application for irritable bowel

Read more
23 Apr 2018 09:47

4D Pharma Loss In 2017 Widens On Higher Research And Development Costs

LONDON (Alliance News) - Drug development firm 4D Pharma PLC said Monday its loss widened in 2017 on higher research and development costs as it continued to progress its pipeline and clinical in

Read more
21 Mar 2018 09:12

4D Pharma To Shortly Begin Clinical Studies On MRx0518 Treatment

LONDON (Alliance News) - 4D Pharma PLC on Wednesday said it is close to starting clinical studies on its potential MRx0518 cancer treatment.MRx0518 is a single strain a

Read more
13 Dec 2016 07:54

4D Pharma Reports Encouraging Results From Blautix Phase 1 Trial

Read more
30 Sep 2016 06:51

4D Pharma Loss Narrows As Operating And Research Costs Fall

Read more
22 Aug 2016 11:57

4D Pharma begins Thetanix phase 1 clinical trial

(ShareCast News) - Pharmaceutical company 4D pharma has begun dosing in a phase 1 clinical trial with Thetanix for the treatment of Paediatric Crohn's disease (PCD). PCD is a rare chronic inflammatory bowel disease that is caused by the malfunction of the immune system leading to inflammation, or sw

Read more
19 Jul 2016 10:00

4D Pharma announces encouraging first clinical trial of Blautix

(ShareCast News) - 4D Pharma announced a positive response from its Blautix treatment for irritable bowel syndrome (IBS) in a phase 1 clinical trial. The trial was a first in man study and, as previously reported by the company, Blautix was found to be both safe and well tolerated and achieved the p

Read more
19 Jul 2016 07:49

4D Pharma Says Positive First Trial Of Product Blautix "Encouraging"

Read more
10 Jun 2016 07:30

4D Pharma Gets Approval To Restart Thetanix Phase I Clinical Study

Read more
23 May 2016 12:49

4D Pharma irritable bowel treatment proves safe in clinical trial

(ShareCast News) - Early clinical trials of 4D Pharma's treatment for irritable bowel syndrome (IBS) have successfully shown Blautix to be safe and well tolerated. Blautix, which contains live bacteria, like all 4D's products, was delivered orally to 56 healthy volunteers and IBS patients. Data fro

Read more
23 May 2016 06:58

4d Pharma Says Blautix Treatment Meets Primary Endpoint In Trial

Read more
17 May 2016 15:11

AGM, EGM Calendar - Week Ahead

Read more
16 May 2016 15:10

AGM, EGM Calendar - Week Ahead

Read more
8 Apr 2016 16:17

4D Pharma gobbles up Biomar production assets

(ShareCast News) - 4D Pharma announced a major acquisition on Friday, gobbling up the production assets of Spanish-based contract research organisation Biomar. The AIM-traded pharmaceutical company, which focuses on the development of live biotherapeutics, said Biomar had been working as an outsourc

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.